ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow
Executive Summary
Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.
You may also be interested in...
SWORD Data Sharpen Commercial Appetite For ViiV’s Juluca, But Is It Too Little Too Late?
ViiV Healthcare has published results from the first long-term Phase III study for switching from a three-drug combination, to an oral two-drug combination. It disproves resistance and safety fears that have hampered prescriber comfort, however, it may have to dampen its sales ambitions when ViiV’s soon-to-be-approved combo Tivicay/Epivir comes to market.
HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End
Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead hopes Biktarvy will enable it to win market share away from ViiV's dolutegravir-containing regimens, but ViiV filed a patent infringement case within hours of the US FDA approval of Gilead's new combo.